Skip to content
value.today

Pelthos Therapeutics Inc.

PTHS
$65 Mmarket cap on Oct 30, 2026
Compare
World rank
#20,347
Revenue
$17 M
For year ending December-2025
Net income
$-43 M
-257.9% margin
SEC filing
Employees
92
As of December 31, 2025
SEC filing

Pelthos Therapeutics Inc. in brief

Pelthos Therapeutics Inc. is a listed company in the Biotechnology industry, based in Durham, North Carolina, USA. Its market value was $65 M on 30 October 2026, which makes it the 20,347th largest listed company in the world and the 3,744th largest in the USA on this site. In the year to December 2025 it had sales of $17 M and a net loss of $43 M. It employs about 92 people. Its largest product and service lines by sales in 2025 were Net product revenues (96%) and License and collaboration revenues (4%). Its shares trade under the symbol PTHS (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI®, and XEGLYZE®.

The July 1, 2025 merger transaction between Channel Therapeutics Corporation and LNHC, Inc., discussed below, resulted in Pelthos Therapeutics Inc. initially having (i) a commercially marketable product, ZELSUVMI for the treatment of molluscum contagiosum, which was launched in July 2025 shortly after the Merger (as defined below); (ii) a manufacturing facility, equipment and know-how to produce the active pharmaceutical ingredient used in ZELSUVMI and the NITRICILTM technology platform; and (iii) clinical-stage assets which selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. In addition, during the fourth quarter of 2025 the Company acquired two additional FDA approved products to expand its commercial product portfolio.

From the company's annual report filed with the US SEC: read the report

Pelthos Therapeutics Inc. timeline

4 events, 2022–2025
  1. 2022
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 🔔
    Initial public offering as Chromocell Therapeutics Corp
    Final prospectus filed with the SEC on 20 February 2024; shares registered for exchange trading on 15 February 2024.
  5. ✎
    Renamed Channel Therapeutics Corp
    Formerly Chromocell Therapeutics Corp.
  6. 2025
  7. ✎
    Renamed Pelthos Therapeutics Inc.
    Formerly Channel Therapeutics Corp.

Events of Pelthos Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$22 M$43 M$65 M$86 M

World rank over time

▼ down 719 places since 2026
2026-10-14: #19675#19,67520262026-10-30: #20394#20,3942026

Rank in USA: #3,617 (Oct 2026) · #3,748 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
3.9×
Price / book
1.7×
Free cash flow yield
-34.9%
Net margin
-257.9%
Operating margin
-193.0%
Return on equity
-111.4%
Liabilities / assets
70.2%
R&D / revenue
7.3%
Revenue per employee
$183 K
Profit per employee
$-471 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue —, net income $-2M—FY22Fiscal year ending Dec 2023: revenue —, net income $-7M—FY23Fiscal year ending Dec 2024: revenue —, net income $-8M—FY24Fiscal year ending Dec 2025: revenue $17M, net income $-43M$17MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$17M—$-32M$-43M-257.9%
Dec 2024——$-8M$-8M—
Dec 2023——$-7M$-7M—
Dec 2022——$-2M$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-23M$0M$-23M$-23.04—
Dec 2024$-6M$0M$-6M$-14.27—
Dec 2023$-1M——$-5.78—
Dec 2022$-2M————

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue $7M, net income $-16M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-22M—Dec ’25Three months to Mar 2026: revenue $11M, net income $-25M$11MMar ’26Three months to Jun 2026: revenue $16M, net income $-23M$16MJun ’26Three months to Sep 2026: revenue $15M, net income $-8M$15MSep ’26

Latest quarter to Sep 2026: revenue $15M (+107.8% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Pelthos Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$17 M
Operating income
$-32 M
Net income
$-43 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$130 M
Total liabilities
$92 M
Total equity
$39 M

As of December-2025

Top 29 institutional investors in Pelthos Therapeutics Inc.#

As of Sep 30, 2026
29 institutions held 1.4 M shares (about 35.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 32.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Pelthos Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Murchinson Ltd.311,019+6,717 (+2.21%)7.91%$7 MNov 13, 2026
2Ikarian Capital, LLC256,5980 (0.00%)6.53%$5 MNov 16, 2026
3AIGH Capital Management LLC256,012-73,086 (-22.21%)6.51%$5 MNov 2, 2026
4Boothbay Fund Management, LLC103,411+1,435 (+1.41%)2.63%$2 MNov 16, 2026
5Vanguard Capital Management LLC95,316-1,818 (-1.87%)2.42%$2 MNov 13, 2026
6Wexford Capital LP84,616+62,252 (+278.36%)2.15%$2 MNov 13, 2026
7Diadema Partners LP80,760+55,987 (+226.00%)2.05%$2 MNov 16, 2026
8Cantor Fitzgerald, L. P.48,124-28,122 (-36.88%)1.22%$1 MNov 16, 2026
9Persistent Asset Partners Ltd20,228+14,221 (+236.74%)0.51%$0 MNov 13, 2026
10Knott David M Jr17,644-4,429 (-20.07%)0.45%$0 MNov 12, 2026
11Geode Capital Management, LLC16,575+1,925 (+13.14%)0.42%$0 MNov 6, 2026
12Citadel Advisors LLC15,453+407 (+2.71%)0.39%$0 MNov 16, 2026
13Ashford Capital Management Inc15,000New0.38%$0 MNov 16, 2026
141492 Capital Management LLC14,577+4,197 (+40.43%)0.37%$0 MNov 12, 2026
15J. Goldman & Co LP13,783-24,292 (-63.80%)0.35%$0 MNov 16, 2026
16Pale Fire Capital SE12,9190 (0.00%)0.33%$0 MNov 13, 2026
17State Street Corp10,800+1,000 (+10.20%)0.27%$0 MNov 12, 2026
18Vanguard Fiduciary Trust Co10,363+490 (+4.96%)0.26%$0 MNov 13, 2026
19BlackRock, Inc.5,093-231 (-4.34%)0.13%$0 MNov 13, 2026
20China Universal Asset Management Co., Ltd.2,360+200 (+9.26%)0.06%$0 MOct 28, 2026
21Vanguard Global Advisers, LLC1,370New0.03%$0 MNov 13, 2026
22UBS Group AG1,224-993 (-44.79%)0.03%$0 MNov 10, 2026
23Nuveen, LLC326New0.01%$0 MNov 10, 2026
24Tower Research Capital LLC (TRC)221+16 (+7.80%)0.01%$0 MNov 16, 2026
25Federation des caisses Desjardins du Quebec60New0.00%$0 MNov 16, 2026
Show all 29: investors 26 to 29
Institutional investors 26 to 29 in Pelthos Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Royal Bank Of Canada47+41 (+683.33%)0.00%$0 MNov 16, 2026
27Farther Finance Advisors, LLC400 (0.00%)0.00%$0 MOct 8, 2026
28Morgan Stanley6New0.00%$0 MNov 13, 2026
29Parallel Advisors, LLC5New0.00%$0 MNov 3, 2026

Mutual funds holding Pelthos Therapeutics Inc.#

9 funds hold shares worth $3 M (about 2.9% of the company). Since their previous reports 6 added shares and 1 sold, buying $0 M net.
Mutual funds holding Pelthos Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.78,008$2 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.16,128$0 M0.41%<0.01%+24%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC7,464$0 M0.19%<0.01%+5.8%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors4,991$0 M0.13%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC2,052$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,972$0 M0.05%<0.01%+14%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.1,818$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.1,180$0 M0.03%<0.01%−44%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC333$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Pelthos Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1000 K
2 purchases, 1 insider
Sold, 12 months
$486 K
24 sales, 5 insiders
Net, 12 months
$514 K
open market only
Insiders on file
11
since
$1000 K-$280 K$0Sep 2024: bought $26 K (5 trades), sold $0 (0 trades)Sep 24Nov 2025: bought $0 (0 trades), sold $280 K (4 trades)NovApr 2026: bought $0 (0 trades), sold $57 K (8 trades)AprMay 2026: bought $0 (0 trades), sold $40 K (1 trades)MayJun 2026: bought $1000 K (2 trades), sold $8 K (2 trades)JunJul 2026: bought $0 (0 trades), sold $56 K (6 trades)JulOct 2026: bought $0 (0 trades), sold $45 K (3 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Pelthos Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Peter GreenleafDirectorSell10b5-1 plan-797$21.17$17 K23,087Form 4
filed Matthew PaulsDirectorSell10b5-1 plan-786$21.00$17 K13,578Form 4
filed Ezra M. FriedbergDirectorSell10b5-1 plan-558$20.72$12 K80,484Form 4
filed Matthew PaulsDirectorSell10b5-1 plan-692$26.00$18 K14,458Form 4
filed Peter GreenleafDirectorSell10b5-1 plan-712$26.00$19 K23,969Form 4
filed Ezra M. FriedbergDirectorSell10b5-1 plan-534$26.03$14 K81,066Form 4
filed Matthew PaulsDirectorSell10b5-1 plan-94$27.36$3 K14,364Form 4
filed Peter GreenleafDirectorSell10b5-1 plan-85$27.27$2 K23,884Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Pelthos Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
158,465
4.9% of shares · 2 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1-for-9.09 reverse split

Trading halts

  • 2026-10-30 13:34 UTC, code M, resumed 13:39 UTC
  • 2026-03-23 15:08 UTC, code M, resumed 15:13 UTC
  • 2025-07-11 16:30 UTC, code M, resumed 16:40 UTC
  • 2025-07-10 13:40 UTC, code M, resumed 13:45 UTC
  • 2025-07-08 13:36 UTC, code M, resumed 13:41 UTC

Fails to deliver

  • : 1,773 shares at $16.54
  • : 671 shares at $15.20
  • : 2,653 shares at $17.00
  • : 1,100 shares at $19.59
  • : 1,032 shares at $18.70

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Pelthos Therapeutics Inc. scorecard#

Passes 3 of the 14 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median3.9×Price to sales 3.9× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-34.9%Free cash flow is -34.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-23.04 vs -14.27Diluted EPS -23.04 in fiscal 2025 against -14.27 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$43 MNet income -$43 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-193.0%-193.0% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-239.5%-239.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.06 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-0.71Z-score -0.71 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year237.5%Diluted shares up 237.5% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Pelthos Therapeutics Inc.'s statements, beside the median of Biotechnology.

Pelthos Therapeutics Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-193.0%-60.5%
Net margin-257.9%-68.9%
Return on equity-239.5%-61.0%
Free cash flow margin-135.1%-61.5%

3of 6on the Piotroski tests of financial strength

  • Net loss of $43 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$23 million.
  • The share count rose 237.5% in the year.
  • Goodwill and intangibles ($64 million) exceed shareholders' equity ($39 million).

Pelthos Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Pelthos Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue170——
Cost of revenue4.00——
Research and development1.21.2r2.60.4
Selling, general and administrative426.4——
General and administrative—4.12.71.1
Operating expenses—7.66.92.3
Total costs and expenses497.6——
Operating income−32−7.6r−6.9−2.3
Interest expense and finance costs3.00.8r0.3r0.1
Other non-operating income (expense)−18−0.4r−0.5−0.1
Income before tax−51−8.0−7.4−2.5
Income tax−7.40——
Net income attributable to shareholders−43−8.0r−7.4−2.5
Earnings per share, basic-23.04-14.27r-5.78r5.65
Earnings per share, diluted-23.04-14.27r-5.78—
Shares, weighted average (basic)1.90.6r1.30.4
Shares, weighted average (diluted)1.90.6r1.3—
Balance sheet
Cash and cash equivalents180.5r0.10.1
Receivables8.90——
Inventory240——
Other current assets3.00.1——
Current assets531.4r0.10.1
Property, plant and equipment9.60——
Right-of-use (leased) assets3.30——
Goodwill250——
Other intangible assets390——
Total assets1301.4r0.10.1
Accounts payable3.01.9r4.63.0
Current liabilities264.1r6.53.8
Lease liabilities (non-current)2.80——
Total liabilities924.1r6.53.8
Retained earnings−65−21r−14−6.1
Shareholders' equity39−2.7r−6.4r−3.7
Total liabilities and equity1301.4r0.10.1
Shares outstanding3.20.6r3.9r1.1
Cash-flow statement
Share-based compensation5.51.8r1.70.1
Cash from operating activities−23−5.8r−1.0−1.6
Capital expenditure−0.10——
Cash from investing activities−5.20——
Debt repaid−0.8−0.2——
Shares issued06.00.3—
Shares bought back0−0.1——
Cash from financing activities456.2r1.01.6
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Pelthos Therapeutics Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Net product revenues$16 M96%
  • License and collaboration revenues$1 M3.5%

Business segments

  • Commercial operations$16 M96%
  • Research and Development operations$1 M3.5%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Pelthos Therapeutics Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Pelthos Therapeutics Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Pelthos Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Financial statements withdrawnFiling
  • Auditor changedFiling
  • Auditor changedFiling

Financial statements withdrawn 1 · Auditor changed 2 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 8 · Material agreement 8 · New debt 6 · Unregistered share sale 5 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 4 · Results announced 7

Pelthos Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Directors and officersShareholder vote8-K
Financial statements withdrawn8-K
Results announced8-K
Auditor changedDirectors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Material agreement8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Acquisition or sale completedResults announced8-K/A
Results announced8-K
Change in controlAcquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Auditor changedMaterial agreementUnregistered share saleShareholder vote8-K
Material agreementNew debt8-K
Directors and officersMaterial agreementNew debtShareholder rights changedBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Pelthos Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$58 MPrivate placement after listing$50 to $250 million7equity, optionsSEC
Nov 2025$18 MPrivate placement after listing$10 to $50 million8optionsSEC
Jul 2025$50 MPrivate placement after listing$50 to $250 million13equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Pelthos Therapeutics Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $330 K a year.

Certified, FY2024
1
#2,047 among companies on value.today
Worker positions
1
Median wage offered
$330 K
a year, full-time
Applications filed
1
Pelthos Therapeutics Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Vice President of Clinical DevelopmentNatural Sciences Managers1$330 K

Where: Freehold, NJ 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Chromocell Therapeutics Corporation

How Pelthos Therapeutics Inc. compares in Biotechnology

  • Market cap$65 M · higher than 30% of 726
  • Revenue$17 M · higher than 49% of 647
  • Net margin-257.9% · higher than 22% of 408
  • Price / sales3.9× · lower than 69% of 339
  • Price / book1.7× · lower than 63% of 534
  • FCF yield-34.9% · higher than 32% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Pelthos Therapeutics Inc.🇺🇸$65 M—-257.9%—
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Pelthos Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Pelthos Therapeutics Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Pelthos Therapeutics Inc.? Suggest a correction